Literature DB >> 15846843

Mapping of phosphorylation sites of nuclear corepressor receptor interacting protein 140 by liquid chromatography-tandem mass spectroscopy.

M D Mostaqul Huq1, Shaukat Ali Khan, Sung Wook Park, Li-Na Wei.   

Abstract

Receptor interacting protein (RIP140) is a versatile coregulator for many nuclear receptors and transcription factors. Analysis by liqid chromatography tandem mass spectroscopy led to the identification of 11 phosphopeptides from tryptic digests of His6-RIP140 purified from Sf21 insect cells. No phosphopeptides were detected on RIP140 expressed in E. coli in a parallel experiment, suggesting that RIP140 phosphorylation occurred specifically only in eukaryotic cells. The tandem mass spectra of the precursor ions of the phosphopeptides were analyzed to map the exact phosphorylation sites on RIP140. All the phosphopeptides displayed intact phosphate containing y- or b-ion signals along with their beta-eliminated product ions, due to neutral loss of phosphoric acid. Phosphorylation occurred specifically on nine serine and a single threonine residues, including Ser-104, Thr-207, Ser-358, Ser-380, Ser-488, Ser-519, Ser-531, Ser-543, Ser-672, and Ser-1003. No tyrosine phosphorylation was found. These data suggested that the central region of RIP140, one major repressive domain, was extensively modified by phosphorylation. These phosphorylation sites can be the targets in future studies addressing post-translational modification of RIP140 with regards to its biological activities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15846843     DOI: 10.1002/pmic.200401090

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  11 in total

1.  Cholesterol regulation of receptor-interacting protein 140 via microRNA-33 in inflammatory cytokine production.

Authors:  Ping-Chih Ho; Kun-Che Chang; Ya-Shan Chuang; Li-Na Wei
Journal:  FASEB J       Date:  2011-02-01       Impact factor: 5.191

2.  Suppression of receptor interacting protein 140 repressive activity by protein arginine methylation.

Authors:  M D Mostaqul Huq; Pawan Gupta; Nien-Pei Tsai; Roger White; Malcolm G Parker; Li-Na Wei
Journal:  EMBO J       Date:  2006-10-19       Impact factor: 11.598

Review 3.  Biological activities of receptor-interacting protein 140 in adipocytes and metabolic diseases.

Authors:  Ping-Chih Ho; Li-Na Wei
Journal:  Curr Diabetes Rev       Date:  2012-11

4.  Gene repressive activity of RIP140 through direct interaction with CDK8.

Authors:  Shawna D Persaud; Wei-Hong Huang; Sung Wook Park; Li-Na Wei
Journal:  Mol Endocrinol       Date:  2011-08-25

5.  Lysine methylation of nuclear co-repressor receptor interacting protein 140.

Authors:  M D Mostaqul Huq; Sung Gil Ha; Helene Barcelona; Li-Na Wei
Journal:  J Proteome Res       Date:  2009-03       Impact factor: 4.466

6.  Modulation of lysine acetylation-stimulated repressive activity by Erk2-mediated phosphorylation of RIP140 in adipocyte differentiation.

Authors:  Ping-Chih Ho; Pawan Gupta; Yao-Chen Tsui; Sung Gil Ha; Mostaqul Huq; Li-Na Wei
Journal:  Cell Signal       Date:  2008-07-05       Impact factor: 4.315

Review 7.  Minireview: role of protein methylation and demethylation in nuclear hormone signaling.

Authors:  Susan C Wu; Yi Zhang
Journal:  Mol Endocrinol       Date:  2009-04-30

Review 8.  Role of nuclear receptor corepressor RIP140 in metabolic syndrome.

Authors:  Meritxell Rosell; Marius C Jones; Malcolm G Parker
Journal:  Biochim Biophys Acta       Date:  2010-12-28

9.  The nuclear receptor transcriptional coregulator RIP140.

Authors:  Patrick Augereau; Eric Badia; Sophie Carascossa; Audrey Castet; Samuel Fritsch; Pierre-Olivier Harmand; Stéphan Jalaguier; Vincent Cavaillès
Journal:  Nucl Recept Signal       Date:  2006-10-30

Review 10.  Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs).

Authors:  Cécile Rochette-Egly; Pierre Germain
Journal:  Nucl Recept Signal       Date:  2009-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.